Clinical trial
Randomized Double Blind Trial Comparing the Efficacy of Prazosin Versus Placebo Associated With Peg-interferon Alpha 2b and Ribavirin for Initial Treatment of Patients With Hepatitis C With Genotype 1 or 4 and Severe Fibrosis (ANRS HC17 PRAZOR)
NCT00148837 is registered in ClinicalTrials.gov with French National Agency for Research on AIDS and Viral Hepatitis as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized Double Blind Trial Comparing the Efficacy of Prazosin Versus Placebo Associated With Peg-interferon Alpha 2b and Ribavirin for Initial Treatment of Patients With Hepatitis C With Genotype 1 or 4 and Severe Fibrosis (ANRS HC17 PRAZOR)
- Lead sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2004
- Completion date
- December 31, 2008
- Enrollment
- 112 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.